← All trials
NCT04999527
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 10, 2021
- Primary completion
- Feb 16, 2022
- Completion date
- Feb 16, 2022
- First posted
- Aug 11, 2021
- Last posted
- Oct 26, 2021
- Enrollment
- 32
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Disc Medicine, IncLead sponsor
- Disc Medicine, IncStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.